tiprankstipranks
Advertisement
Advertisement

GB:0MGB Stock Latest News

Genmab reports Darzalex Q1 worldwide sales $3.964B
The FlyGenmab reports Darzalex Q1 worldwide sales $3.964B
9h ago
JNJ
GMAB
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
PremiumRatings
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
12h ago
GMAB
Genmab presents safety, tolerability data on Rina-S with bevacizumab
PremiumThe Fly
Genmab presents safety, tolerability data on Rina-S with bevacizumab
1d ago
GMAB
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
18d ago
TW
AGX
Genmab initiated with an Outperform at Wolfe Research
PremiumThe Fly
Genmab initiated with an Outperform at Wolfe Research
19d ago
GMAB
Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
PremiumThe FlyNetflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
1M ago
AZZ
FPS
Genmab initiated with an Overweight at Wells Fargo
Premium
The Fly
Genmab initiated with an Overweight at Wells Fargo
1M ago
GMAB
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
Premium
Ratings
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
2M ago
GMAB
Genmab price target lowered to $40 from $45 at Guggenheim
PremiumThe Fly
Genmab price target lowered to $40 from $45 at Guggenheim
2M ago
GMAB
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
PremiumRatings
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
2M ago
GMAB
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
PremiumRatings
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
2M ago
GMAB
Genmab price target raised to $40 from $39 at H.C. Wainwright
PremiumThe Fly
Genmab price target raised to $40 from $39 at H.C. Wainwright
2M ago
GMAB
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
PremiumRatingsGenmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
2M ago
GMAB
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
Premium
The Fly
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
2M ago
JNJ
GMAB
Genmab resumed with a Buy at Jefferies
Premium
The Fly
Genmab resumed with a Buy at Jefferies
2M ago
GMAB
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
PremiumRatings
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
2M ago
GMAB
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
PremiumRatings
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
2M ago
GMAB
Genmab resumed with an Equal Weight at Morgan Stanley
PremiumThe Fly
Genmab resumed with an Equal Weight at Morgan Stanley
2M ago
GMAB
0MGB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
0MGB Upcoming Earnings Report: What to Expect?
2M ago
AI Daily: Nvidia invests $2B in CoreWeave
PremiumThe FlyAI Daily: Nvidia invests $2B in CoreWeave
3M ago
LLY
NVS
Drugmakers use AI to help progress through trials, submissions, Reuters says
Premium
The Fly
Drugmakers use AI to help progress through trials, submissions, Reuters says
3M ago
GSK
LLY
Genmab reports worldwide net sales of Darzalex in 2025 totaled $14.351B
Premium
The Fly
Genmab reports worldwide net sales of Darzalex in 2025 totaled $14.351B
3M ago
JNJ
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >